Greenland Mines Ltd.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Greenland Mines Ltd is a Nasdaq-listed strategic minerals explorer and developer focused on natural resources and cell and gene therapies. The company operates in two main divisions: Natural Resources, pursuing exploration and development opportunities in palladium, gold, and platinum deposits, including the Skaergaard Project in Southeast Greenland; and Cell and Gene Therapy, advancing biologic, cell, and gene therapies targeting neurodegenerative and age-related diseases such as Alzheimer's, ALS, and Parkinson's. Greenland Mines is headquartered in Frankfurt am Main, Germany, and established in 2019; it maintains geographic reach across Greenland, North America, Europe, and selected global markets through strategic partnerships and investor relations channels. The company’s principal products and services span mineral exploration and development activities, precious and strategic metal resource opportunities, and early- to mid-stage clinical and translational therapy programs, including partnerships with biomedical entities to advance KLTO-202 for ALS and related indications. Core offerings are organized as: mineral exploration rights and project development services; resource delineation, feasibility studies, and permitting support; project finance and investment opportunities for mineral assets; and research, development, and potential commercialization of cell and gene therapies in preclinical and clinical stages; and corporate services including investor outreach, strategic alliances, and licensing opportunities. Greenland Mines’ recent major changes include forming and expanding strategic alliances to accelerate mineral asset development in Greenland and associated jurisdictions, pursuing acquisitions and partnerships to broaden its asset base in lithium and rare earths, launching new programs or pilots in high-potential districts, and pursuing potential corporate restructurings to align with growth objectives; these actions reflect a shift toward accelerated value creation through asset diversification, enhanced capital deployment, and advancement of pipeline therapies. The company’s business segments address both commodity markets and biotechnology, with target markets comprising institutional investors, mining and metals customers, pharmaceutical and biotech partners, and governmental and regulatory bodies. Subsidiaries and parent relationships are oriented toward maintaining a public listing while leveraging strategic joint ventures and alliance agreements to maximize project value and therapy program progression. Greenland Mines’ operations are anchored in Greenland’s mineral districts, with ancillary activities in Canada and other jurisdictions to support project financing, regulatory compliance, and potential downstream opportunities; the company emphasizes geographic accessibility, robust governance, and transparent disclosure in line with Nasdaq-listed peers. This combined approach positions Greenland Mines as a dual-sector platform aiming to generate returns from high-value mineral discoveries while advancing novel therapeutic modalities for neurodegenerative and age-related diseases.
Company News
Greenland Mines Shareholder Letter Recaps Six Months of Achievement; Highlights Coming Milestones for Q4 2026
Greenland Mines Completes Acquisition of World-Class Rare Earth Nd-Pr Magnet and Defense Mine Asset Following Greenland Government Approval
Greenland Mines Set to Close Sarfartoq Rare Earths Acquisition by Sept. 1, 2026
Greenland Mines Announces Pricing of $20 Million Public Offering
Greenland Mines Announces Proposed Public Offering
Greenland Mines Outlines $2B Valuation for Sarfartoq Project
Greenland Mines Sarfartoq Nd-Pr Rare Earth Project Valued Up to US$2.05 Billion With Pre-Tax IRR of 118.6% and Significant Additional Upside Potential
Greenland Mines Delivers Landmark S-K 1300 Mineral Resource Estimate for Sarfartoq in Greenland; First-Ever Indicated Resource and First Combined Open Pit/Underground Resource for the Critical Nd-Pr Magnet Rare Earths Project
Greenland Government Approves Rare Earths License Transfer to Greenland Mines
Greenland Mines Provides Corporate and Operational Update; Announces 1-for-50 Reverse Stock Split
Greenland Mines Delivers Two Key Milestones at Skaergaard: Bathymetric Survey Completed, Initial Metallurgical Core Drilling Concluded
Greenland Mines Arrives at Skaergaard, Commences Drilling as 2026 Field Season Moves into Full Operation
Greenland Mines Departs for Skaergaard – Expanded 2026 Program Targeting Next Phase of Development
Biotech Division of Greenland Mines Announces Issuance of Patent in Canada for the Klotho Gene Therapy Platform Technology for Alzheimer's and Aging
Greenland Mines Announces Limited-Duration Stockholder Rights Plan Intended to Protect Shareholder Value
Greenland's Palladium Answer Just Got 31% Bigger, and Washington Is Watching
Greenland Mines Reports 36–44% PdEq Grade Uplift and +31% Increase in Indicated PdEq Ounces at its Skaergaard Gold, Palladium, Platinum Project in First S-K 1300 Technical Report Summary
Biotech Division of Greenland Mines Announces Australian Patent Grant for Klotho Gene Therapy Technology for Treatment of Neuromuscular Diseases
Greenland Mines Adds World Class Magmatic Researchers and Greenland Specialists to 2026 Skaergaard Field Campaign
A Drilling Crew, an Icebreaker, and a Path to an Open Pit at Skaergaard